No description available.

No description available.

Fes was first discovered as a protein-tyrosine kinase-encoded by the v-fes retroviral oncogene. Retrovirally encoded Fes oncoproteins induced tumors in chickens and cats and cause tumors in transgenic mice; however, a role for Fes in human cancer has not been established. This thesis identifies tumor promoting roles of Fes through effects on stromal cells using genetic mouse models. First, in an orthotopic mouse mammary gland engraftment model, I found that loss of Fes in the host correlated with reductions in engrafted tumor growth rates, metastasis and circulating tumor cells, which may be partly due to reduced vascularity and fewer tumor-associated macrophages. We also showed Fes-deficient macrophages were less capable of promoting tumor cell invasion in co-culture experiments. Next, I observed delayed tumor onset in the absence of Fes in a transgenic mouse model of breast cancer driven by an activated HER2/Neu allele. This longer tumor latency correlated with hyperinflammatory status of Fes-deficient normal mammary glands. Taken together, these observations argue that Fes inhibition might provide therapeutic benefits in breast cancer, by attenuating tumor-associated angiogenesis and the metastasis-promoting functions of tumor-associated macrophages, or by delaying breast tumor onset in women with HER2 overexpression. Finally, we showed that mice engrafted with IL-4 producing tumor cells developed tumors with significantly reduced growth rates and a complete attenuation of lung metastasis, which correlated with increased numbers of macrophages and enhanced phagocytic capability of macrophages in the tumor microenvironment. These observations suggest that IL-4 could be a good candidate for immunotherapy. / Thesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2013-12-18 11:44:40.294

Flaxseed oil (FO), rich in α-linolenic acid, has been shown to inhibit breast cancer growth. One suggested mechanism is through modulation of HER2 expression and signalling. This study determined the effect of FO on the growth of established HER2-overexpressing breast tumours (BT-474) and its interaction with two doses of a primary anti-HER2 therapy, trastuzumab (TRAS), in athymic mice. FO alone had no effect on tumour size, cell proliferation and apoptosis. TRAS (2.5 and 5 mg/kg) reduced tumour size and cell proliferation but had no effect on apoptosis. TRAS (2.5 mg/kg) combined with FO reduced tumour size and cell proliferation and increased apoptosis compared to TRAS (2.5 mg/kg) alone and was just as effective as 5 mg/kg TRAS. TRAS (5 mg/kg) resulted in almost complete tumour regression with or without FO. In conclusion, FO has no effect on BT-474 tumour growth but can enhance the effectiveness of low dose TRAS.

The human Fyn-related kinase (FRK) is a member of subfamily of Src-related kinases family. FRK is 54 kDa non-receptor tyrosine kinase protein composed of 505 amino acids. FRK consists of three functional domains: Src homology 3 (SH3), SH2 and kinase domain, as well as a putative tyrosine kinase regulator at the C-terminus. FRK has a conserved auto-regulatory tyrosine residue within its kinase domain. It has been reported that FRK is repressed in about 30 % of human breast cancer samples. Over-expression of FRK in breast cancer cells of the mammary gland was shown to suppress cell growth by interacting, phosphorylating and stabilizing the tumor suppressor PTEN, thus inhibiting AKT/PI3K signaling. Although it has been suggested that FRK is a tumor suppressor gene, the effects of activated FRK on cell proliferation, migration and invasion are unclear. Likewise, the signaling pathways regulated by the activation of FRK have not been yet fully characterized. We hypothesize that the activation of FRK is essential for the regulation of its cellular functions. Mutation of the C-terminal auto-regulatory tyrosine 497 to phenylalanine (FRK-Y497F) resulted in the constitutive activation of FRK. We generated stable cell lines expressing either the FRK wild type (FRK-WT) or FRK-Y497F from triple negative breast cancer MDA-MB-231 cells. The introduction of FRK-Y497F in MDA-MB-231 cells significantly suppressed their proliferation, migration, invasiveness and colony formation as compared to cells that expressed the FRK-WT gene. Over-expression of either FRK-WT or FRK-Y497F in MDA-MB-231 cells inhibited the phosphorylation of AKT, STAT3, JNK and P38 MAPK as compared to either the MDA-MB-231 parental cells or those that were transfected with the empty vector. Our results suggested that FRK represses cell proliferation, migration, invasiveness and colony formation at least in part by the inhibiting the activation of AKT/PI3K, JAK-STAT and MAPK signaling pathways.

Fifteen years ago, the Steroid receptor RNA activator (SRA) was identified as a functional non-coding RNA able to increase the activity of the estrogen receptor (ER), a critical player mediating the mitogenic role of estradiol in breast cancer. Interestingly, four years later, SRA appeared to be the first ever discovered functional RNA also able to encode a protein (SRAP). As such, the products of the SRA1 gene delineate a fascinating bi-faceted system involving both a functional RNA and a protein. Since its discovery, the non-coding aspect of this system has been widely investigated, with multiple groups gathering information on SRA structure and related functions. Overall, the non-coding SRA transcript is thought to act as a broad co-regulator modulating the activity of different transcription factors. Conversely, limited information has been obtained on the coding aspect (SRAP) of this system，even though SRA/SRAP is currently believed as a whole to be involved in several mechanisms including tumourigenesis, tumour progression, myogenesis and adipogenesis. In this body of work, I have attempted to define the clinical relevance of SRAP to breast cancer and extend the understanding of the cellular processes potentially regulated by this protein. I have first established that SRAP had the potential to become a new prognostic and predictive factor in specific groups of patients. Indeed, I have demonstrated, using tissue microarray analyses (TMAs), that SRAP expression was up-regulated in some breast tumours, with high levels associated with poor prognosis in Estrogen Receptor (ER) positive breast cancer patients. Using the same technique, I have further identified a positive association between a positive response to tamoxifen treatment and a high level of SRAP expression in a large cohort of ER-α negative cases. This highlights the potential for SRAP to become a new predictive factor of response to endocrine therapy in this specific group of patients. Using RNA-seq to define the transcriptomes of cervical Hela and breast MDA-MB-231 cancer cells upon depletion or overexpression of this protein, I further identified cellular movement amongst the potential cellular processes affected by changes in SRAP expression. Using classical trans-wells assays as well as an live-cell imaging assays, I have confirmed that SRAP indeed regulates individual cancer cell motility. Overall, my results provide critical new insights into the potential functions of the protein counterpart of the intriguing SRA/SRAP bi-faceted gene system. SRAP herein appears as a potential new therapeutic target in the fight against breast cancer that remains to be further investigated. / February 2017

No description available.

Breast cancer is the most common cause of cancer death in Australian women. Current pathological analysis examines a small section of tissue for cellular and plasma abnormalities using a light microscope. However, this method of diagnosis, despite being the current gold standard, has its limitations, where human error and professional experience can influence a patient’s diagnosis. A potential alternative or adjunct to conventional histopathology for classifying tissue disease status is offered by Small Angle X-ray Scattering (SAXS). At the time of commencement of this work, there had been several small scale studies which examined the potential of SAXS to classify the disease status of breast tissue. These tended to focus on the supramolecular structure of collagen fibrils found in the breast, where it is known that the degradation of these fibres is related to the spread of disease. Most previous studies also used a synchrotron as an X-ray source, due to the intense and highly collimated flux available. This study used a synchrotron source, but also evaluated the use of a laboratory X-ray source, as a more convenient and relatively inexpensive alternative that could one day find application in the clinic. The work presented in this thesis analyses the largest cohort of patients and breast tissue samples studied to date using SAXS: 130 patients with 543 tissue samples. Tissues were sourced from surgical waste and classified into four groups: invasive carcinoma, benign, normal, and mammoplasty. Mammoplasty tissue samples were harvested from patients undergoing breast reduction and/or reconstruction, where no history or presence of disease was indicated. Normal tissue was sampled from patients with known disease, but pathological analysis of the tissue core diagnosed it as normal. A comprehensive analysis of the scattering patterns was carried out, analysing features arising from the collagen structure and orientation, the total scattered intensity, and adipose tissue in the breast. Features related to the axial D-spacing of the collagen fibrils within the breast tissue as well as the integrated scattering intensity (called amorphous scatter) demonstrated the highest ability to discriminate tissue types, in SAXS images acquired from both the synchrotron source and the laboratory X-ray source. The amorphous scatter intensities obtained using a synchrotron source showed highly significant differences (p < 0.01) for almost all of the tissue pair comparisons: invasive carcinoma vs. benign, invasive carcinoma vs. normal, invasive carcinoma vs. mammoplasty, benign vs. mammoplasty, and normal vs. mammoplasty. However, no significant difference was seen in the amorphous scatter between benign versus normal tissues (p = 0.30). The amorphous scatter values increased with severity of disease, i.e. it was the highest for invaded tissues and decreased progressively from benign to normal to mammoplasty. There was a significant difference between normal and mammoplasty tissue types using the amorphous scatter as a discriminator (p = 0.0025). Pathological assessment cannot differentiate between these two tissue types, which suggests that there may be changes occurring in these tissue structures at the supramolecular level that can be characterised using SAXS. The ability of SAXS to reveal structural differences between normal and mammoplasty tissue types is highly significant, for both disease diagnosis and treatment, as well as for understanding disease progression. For example, these differences might aid in determining surgical margin clearance of excised breast lesions as well as potentially provide a means of pre-screening or perhaps improve false-negative rates of diagnosis. The potential of SAXS to reveal macroscopic extent and directional spread of disease was explored using two-dimensional mapping of the amorphous scatter. These maps showed broad agreement with histopathological diagnosis, but further investigation regarding their reliability and interpretation for clinical utility is still needed. Changes in both the amorphous scatter and the axial D- spacing were seen in tissue samples up to 6 cm away from the primary site of disease. In particular, a significant decrease in both parameters was seen between the centre of the tumour (at 0 cm) and 2 cm away, suggesting that closer examination of the tissue structures over the disease/healthy tissue border may provide information regarding the mechanisms of metastasis and growth of cancerous tumours. The combination of the amorphous scattering results from the two X-ray sources indicates that the size of the scatterers may be the key in classifying tissue types. The synchrotron source was able to access a lower q-range (q = 0.1-0.6 nm-1) and the laboratory source covered a larger q-range (q = 0.25-2.3 nm-1). Mammoplasty tissues appear to be characterised by large scattering components (d > 25.13 nm), whereas normal tissues are characterised by slightly smaller scattering components (10.47 nm < d < 25.13 nm) and benign tissues by even smaller scattering components (4.83 < d < 10.47 nm). It appears that the size of the scatterers contributing to the total scattering intensity decreases with severity of disease, which was seen independently with both X-ray sources. Further investigation is warranted to determine the biological origin of these differences. These results also suggest that the optimum SAXS instrument may need to cover a scattering vector range of q < 0.25 nm-1 to identify differences in healthy tissue types, and q > 2.3 nm-1 to possibly investigate invasive carcinoma tissue types. A SAXS apparatus that can examine a large q-range may provide all of the necessary information from the amorphous scatter to differentiate between tissue groups. The periodic structure of collagen fibrils along their longitudinal axis can be characterised by the axial D-spacing, where this spacing was found to change with the presence of disease. The axial D-spacing for healthy breast tissues was found to be significantly lower in normal and mammoplasty tissues compared to invaded tissues (p = 0.0050 and p = 0.0093, respectively). However, no significant differences between the other tissue group pairs were seen (p > 0.05). These differences were evident in classification modelling of the four tissue groups, where the amorphous scatter and the amplitude of a collagen axial peak were used to build a probability model for disease status. The model showed high sensitivities (> 70%) and widely variable specificities (ranged from 18-97%) for the data examined with the synchrotron source. This means that the model was a good indicator of disease, but poor at indentifying healthy tissue types. The work presented in this thesis shows that SAXS is capable of distinguishing breast tissue types with high sensitivity and has the potential to become a significant tool for the investigation of cancer progression or even diagnosis. Further investigation into the amorphous scatter and axial D-spacing in particular may provide insight into the biological mechanisms related to tissue degradation associated with invasive disease.

Loss of proliferative control is a cornerstone of cancer development, induced by deregulation of mitogenic signalling, insensitivity to anti-proliferative signals and direct changes in cell cycle proteins. In breast cancer these alterations are frequently targeted through cyclins D1 and E, leading to defects in G1/S transition. I have investigated the role of two potential pro-proliferative oncogenes in breast cancer, id1 andwt1. Each protein promotes proliferation in distinct contexts, with unique consquences for breast cancer cells. Using a 3D culture model of non-transformed mammary epithelial cells, I identified that id1 undergoes downregulation via rapid proteosomal degradation and cytoplasmic relocalisation during mammary epithelial morphogenesis. Overexpression of Id1 led to an increase in acinar size via an increase in S phase, and wa dependent on the presence of an intact HLH domain in Id1. Co-expression with the proto-oncogene Bcl2 led to a more disorganised acinar structure, indicating that Id1 overexpression primed the cells for further oncogenic insult. Further, Id1 overexpression was unable to increase acinar size in cyclin D1-/- acini, indicating that Id1 is dependent on cyclin D1 for its proliferative effects. Overall these data identified Id1 as capable of altering the proliferation of normal mammary epithelial cells, a crucial step in early breast carcinogenesis. Wt1 was originally identified as a tumour suppressor, but our data lends support to Wt1 acting as an oncogene in breast cancer. Wt1 is expressed highly in a range of breast cancer cell lines, and is strongly regulated by progestins. Using siRNA, we identified that Wt1 is likely to be a molecular intermediary of progestin as the downregulation of Wt1 mimics a subset of progestin effects on cell proliferation and lipid synthesis. Conversely, the overexpression of the major Wt1 isoform, Wt1 (+/+), led to attenuation of progestin-induced differentiation and growth arrest via maintenance of cyclin D1 levels. The effects of Wt1 overexpression were specific to progestins, and did not affect the actions of anti-estrogens or androgens. Consequently the overexpression of Wt1 (+/+) may disrupt the endocrine response in mammary epithelial cells, and contribute to excess proliferation and failure to differentiate during breast oncogenesis.

Breast cancer is the most common cancer and the leading cause of cancer-related death among Canadian women. Despite improvements in treatment and early detection, there is still a need to develop novel therapies for breast cancer management. Aberrant Notch signaling is tumorigenic and is associated with poor clinical outcomes in breast cancer, as well as in several other types of cancer. Activation of Notch signaling requires -secretase-mediated Notch receptor cleavage. Thus, strategies to inhibit Notch signaling, including -secretase inhibition, are being evaluated for potential anti-tumor effects. The strongest justification for targeting Notch in breast cancer, and more specifically for using -secretase inhibitors, came from two studies that reported that the -secretase inhibitor (GSI) Z-LLNle-CHO inhibited the growth of breast cancer cells both in vitro and in vivo without causing significant side effects. In Chapter 2, we compared the enzymatic activities and cytotoxicity of Z-LLNle-CHO to those of two other specific GSIs and three proteasome inhibitors and demonstrated that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by -secretase inhibition. In Chapter 3, we characterized the protein complexes formed in breast cancer cells by the intracellular domains (NICD) of the four Notch paralogs. We found that the assembly of NICD protein complexes is dose-dependent and availability of MAML proteins becomes the limiting factor for continuous formation of NICD/RBPj/MAML transactivation complex. This suggests that the formation of some non-canonical NICD complex might occur preferentially at high levels of NICD, conditions under which aberrant Notch signaling induces tumorigenesis in breast cancer. Consequently, these non-canonical interactions might be good targets to specifically block oncogenic, but not physiological, Notch signaling. In addition, we found that the relative affinities of individual NICD paralogs to several known NICD-interacting proteins were different. This may account for the paralog-specific activities of Notch that have been previously reported. Together, these results may be of value for the development of new reagents to block Notch signaling for therapeutic benefit in breast cancer treatment. / Experimental Oncology